To the Editor,

A 43-year-old female with past medical history of Crohn's disease (CD), bronchial asthma, and congenital heart disease presented to an outside hospital with cough and nonbloody diarrhea. She had a prior history of ileo-colonic resection in 2008 and was on 90 mg of ustekinumab every 8 weeks and 150 mg of 6-mercaptopurine daily. Upon admission, her vitals were significant with a blood pressure of 96/52 mm Hg, heart rate of 111, oxygen saturation of 98% at room air, and a temperature was 99.6°F. C-reactive protein was 5 mg/L (N \< 8 mg/L). Her chest x-ray was normal. Nasopharyngeal samples taken for SARS-CoV-PCR test were negative. Colonoscopy revealed end-to-end patient ileocolic anastomosis and Rutgeerts score i1. She received intravenous methylprednisolone for asthma, and she was discharged home.

One week later, she returned to our emergency department due to worsening shortness of breath, fatigue, and fever, along with nonbloody diarrhea. Reverse transcription polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 by nasopharyngeal swab was positive. At presentation, her vitals were significant with a fever of 100.5°F and a heart rate of 112. Her chest x-ray was normal. Her white blood cell count was low at 2.41. She was admitted and managed with supportive measures; no treatment specific for coronavirus 2019 (Covid-19) was given, and she was discharged home after 3 days. Subsequent repeat RT-PCR testing for SARS-CoV-2 by nasopharyngeal swab was positive after 15 days of initial presentation. The patient was completely asymptomatic after the initial 4 days. Biologic treatment and 6-mercaptopurine was held. Subsequently, she had a repeat RT-PCR testing for SARS-CoV-2 by nasopharyngeal swab twice and was finally negative after 22 days of initial presentation.

This case is of interest for 2 reasons. Our patient had prolonged duration to clear the SARS-CoV-2. In a recent study, the median viral positivity duration was 12 days.^[@CIT0001]^ Immune cells including CD8+ T cells and eosinophils have been reported to be critical for viral clearance in acute infections such as coronavirus.^[@CIT0002],\ [@CIT0003]^ Count of CD8+ T cells was shown to be the predominant risk factor for the SARS-CoV-2 viral positivity duration.^[@CIT0001]^ Whether the use of biologics and immunomodulators could alter the CD8 lymphocyte levels resulting in prolonged duration of SARS-CoV-2 as seen in our patient is yet to be seen. The second interesting finding is that the patient had multiple risk factors for poor outcomes including bronchial asthma, congenital heart disease, CD on dual treatment with biologics and immunomodulator, and corticosteroid use (for bronchial asthma) and still recovered rapidly within 4 days. Because Covid-19 binds ACE 2, which is downregulated in CD patient in remission, our patient could have had a rapid recovery.^[@CIT0004]^ Future studies should investigate the duration of SARS-CoV-2 positivity in IBD patients and their potential for significant asymptomatic transmission and the impact of immunomodulation on Covid-19 outcomes.
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